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Abstract Obesity is a complex disorder caused by sev-
eral factors. Thus, the aim of the present study was to
assess whether the expression of genes in the omental
white adipose tissue (AT) of subjects with insulin resis-
tance (IR) or metabolic syndrome (MetS) is associated with
an elevation in serum branched-chain amino acids
(BCAAs) and whether this response depends on specific
genetic variants. Serum BCAA concentration, the adipo-
cyte area, and gene variants of PPARc, ABCA1, FTO,
TCF7L2, GFOD2, BCAT2, and BCKDH were determined
in 115 Mexican subjects. The gene expression in the AT
and adipocytes of BCAT, BCKDH E1a, C/EBPa, PPARc2,
SREBP-1, PPARa, UCP1, leptin receptor, leptin, adipo-
nectin, and TNFa was measured in 51 subjects. Subjects
with IR showed higher values for the BMI, HOMA-IR, and
adipocyte area and higher levels of serum glucose, insulin,
leptin, and C-reactive protein, as well as an elevation of the
AT gene expression of SREBP-1, leptin, and TNFa and a
significant reduction in the expression of adiponectin,
BCAT2, and BCKDH E1a, compared with non-IR subjects.
The presence of MetS was associated with higher HOMA-
IR as well as higher serum BCAA concentrations. Subjects
with the genetic variants for BCAT2 and BCKDH E1 a
showed a lower serum BCAA concentration, and those
with the ABCA1 and FTO gene variant showed higher
levels of insulin and HOMA-IR than non-IR subjects. AT
dysfunction is the result of a combination of the presence
of some genetic variants, altered AT gene expression, the
presence of MetS risk factors, IR, and serum BCAA
concentrations.
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Introduction
The incidence of obesity has increased dramatically in
recent decades. Omental white adipose tissue (AT) dys-
function is a primary defect in obesity and may link obesity
to several health problems, including increased risk for
insulin resistance (IR), type 2 diabetes, fatty liver disease,
hypertension, dyslipidemia, and some cancers. For obese
men (BMI C 30 kg/m2), the risk of developing type 2
diabetes is 9-fold higher than for lean men (Weinstein et al.
2004). Adipocyte dysfunction could be caused by different
factors, including the presence of specific gene variants,
disequilibrium in adipocyte gene regulation, the presence
of risk factors for metabolic syndrome (MetS), and the
presence of some other metabolites. Previous reports have
described an association between branched-chain amino
acids (BCAAs) and IR and a strong correlation between
serum BCAA and obesity (Newgard et al. 2009; Tai et al.
2010) and have indicated that BCAA concentration is a
predictor of the progression of diseases such as diabetes
(Shah et al. 2012; Wang et al. 2011).
However, it is not known how the levels of BCAAs
increase in subjects with obesity and IR; several possibil-
ities do exist, though. One contributor could be the tissue-
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specific expression of genes encoding key BCAA catabo-
lism enzymes. The main amino acid-catabolizing enzyme
in BCAA catabolism is the mitochondrial branched-chain
aminotransferase (BCAT2), which catalyzes the transami-
nation of the three BCAAs, leucine, isoleucine, and valine,
to the corresponding branched-chain keto acids. A second
enzyme, branched-chain keto acid dehydrogenase, cata-
lyzes the formation of the corresponding acyl CoA deriv-
atives from the branched-chain keto acids (Harper et al.
1984). Interestingly, recent findings have demonstrated that
AT contributes to the alterations of BCAA metabolism of
metabolically compromised individuals compared to sub-
cutaneous adipose tissue indicating the importance of AT
in the modulation of circulating BCAA levels (Lackey
et al. 2013). The second contributor to the higher serum
BCAA during obesity could be the presence of specific
gene variants of BCAA enzymes, although this contribu-
tion must still be elucidated. Studies have reported that the
frequency of the genetic variants BCKDH and BCAT2 is 25
and 12 %, respectively, in the American population
(EMBL-EBI 2013). The third contributor could be AT
dysfunction. AT plays an important role in BCAA catab-
olism because this organ has a large capacity for trans-
amination and oxidative decarboxylation of BCAA after
skeletal muscle (Brosnan and Brosnan 2006). For this
reason, AT could be a key player in obesity-related meta-
bolic dysfunctions. Thus, the aim of the present study was
to understand the role of BCAA metabolism in IR and
MetS and to provide a global view of the interactions
between genetic variants, inflammation, IR, BCAA
metabolism, cytokines, and AT gene expression.
Materials and methods
Participants
This study was performed at the Department of Physiology
of Nutrition of the Instituto Nacional de Ciencias Me´dicas
y Nutricio´n, Salvador Zubira´n (INCMNSZ), Mexico City.
We included Mexican Mestizos subjects of both genders,
with ages between 18 and 65 years, who underwent an
elective laparoscopic surgery. AT of control subjects was
obtained from patients that underwent Nissen fundoplica-
tion for hiatus hernia, Heller cardiomyotomy type for
achalasia, and elective cholecystectomy for chronic cho-
lecystitis. Biopsies of the intra-abdominal omental fat
depots were collected in Krebs–Ringer buffer. Mexican
Mestizos were considered only those individuals who had
been born in Mexico for three generations. These indi-
viduals are descendant of the original autochthonous
inhabitants of the region and of individual, mainly Span-
iards, of Caucasian and/or African origin, who came to
America during the sixteen century (Vargas-Alarcon et al.
2014). We excluded subjects with diabetes and patients
who were undergoing treatment for dyslipidemia, hyper-
tension, thyroid diseases or obesity with a low calorie diet
to eliminate the possible effect of medications on clinical
and biochemical parameters and also excluded subjects
with other chronic disease and pregnant women. The study
was approved by the ethics committee of the INCMNSZ,
and all subjects gave written informed consent.
Anthropometric measurements
A complete physical examination was performed on each
patient. The anthropometric evaluation included measure-
ments of the body weight, height, and waist circumference
(WC) (Lohman and Martorell 1998). The percentage of fat
mass and lean mass was obtained using a whole body
composition analyzer (e-Body 205, Jawon Medical) in the
morning after 12 h of fasting. The nutritional status of the
subjects was evaluated by BMI classification according to
the World Health Organization (Obesity: preventing and
managing the global epidemic. Report of a WHO consul-
tation 2000).
Biochemical parameters
Blood samples were collected after a 12 h fasting period on
the same day of elective surgery prior to surgical anes-
thesia. Serum total cholesterol (TC), triglycerides (TG),
and HDL were determined using a Synchron CX5D ana-
lyzer (Beckman Coulter, CA, USA), and LDL was calcu-
lated using the Friedewald formula (Friedewald et al.
1972). Total serum adiponectin and leptin were measured
using an ELISA kit (Millipore, Billerica, MA, USA).
C-reactive protein (CRP) was measured by a high-sensi-
tivity ELISA (CardioPhase hs-CRP, Siemens Health
Diagnostics, Marburg Germany). Glucose was determined
using the glucose oxidase method (Boehringer, Mannheim,
Germany). Insulin was measured by an enzyme immuno-
assay (ALPCO Diagnostics, Salem NH, USA).
Branched-chain amino acids
Serum BCAA levels were determined using a colorimetric
assay kit following the manufacturer’s instructions (Ab-
cam, Cambridge MA) with leucine as a standard.
Genotyping
DNA was extracted from leukocytes (Miller et al. 1988).
Single nucleotide polymorphisms (SNPs) of BCKDH
rs45500792, BCAT2 rs11548193, ATP–binding cassette
transporter A1 (ABCA1) rs 9282541, fat mass- and obesity-
431 Page 2 of 10 Genes Nutr (2014) 9:431
123
associated gene (FTO) rs 9939609, glucose-fructose oxi-
doreductase domain containing 2 (GFOD2) rs 12449157,
peroxisome proliferator activated receptor c (PPARc)
rs1801282, and transcription factor 7-like 2 (TCF7L2)
rs7903146 were determined by an allelic discrimination
using a PCR endpoint TaqMan SNP Genotyping assay
(ABI Prism 7900 HT Sequence Detection System, Applied
Biosystems, Foster City CA, USA) (Tsai et al. 2010).
These genotypes were distributed according to the Hardy–
Weinberg equilibrium (Emigh 1980).
Adipocyte area
The area of adipocytes was measured with ImageJ 1.42p
digital imaging processing software (Rasband 1997–2012).
Omental adipose tissue and adipocyte RNA isolation
and real-time quantitative RT-PCR
An AT sample was obtained from a subgroup of 51 sub-
jects, and adipocytes were isolated from AT as previously
described (Frigolet et al. 2011). Total RNA was extracted
from AT and adipocytes as previously described (Chom-
czynski and Sacchi 1987) followed by the measurement of
RNA integrity, concentration and purity. The mRNA
abundance was measured by real-time quantitative PCR
using Taqman Assays (Applied Biosystems). Assays for
each gene were conducted in triplicate in 96-well optical
plates with a sequence detection system (ABI Prism 7000,
Applied Biosystems). All data were normalized to house-
keeping gene [low-density lipoprotein receptor-related
protein 10 (LRP10) or cyclophilin] using the CT method.
The relative amounts of all mRNAs for samples were
calculated by the comparative CT method) (Livak
and Schmittgen 2001). Relative mRNA expression in adi-
pose tissue was calculated based on the efficiency
(E = [-1/slope]) of the primer/probe hybridization, and the
threshold cycle (CT) values deviation between each sample
and the control were expressed in comparison to the ref-
erence gene (LRP10) based on equation described previ-
ously (Tovar et al. 2011).
Patients were classified into groups according to the
presence of IR or MetS. IR was evaluated and considered
present when HOMA-IR was C2.5 (Almeda-Valdes
et al. 2010). HOMA-IR was calculated as follows:
HOMA = glucose (mmol/l) 9 insulin (pg/ml)/22.5)
(Matthews et al. 1985). MetS was defined as the presence
of at least three of the following factors: WC C 90 cm in
men and C80 cm in women, TG C 1.7 mmol/l,
HDL \ 1 mmol/l in men and \1.3 mmol/l in women,
systolic blood pressure C 130 mmHg or diastolic blood
pressure C 85 mmHg, and fasting glucose C 5.6 mmol/l
(Alberti et al. 2009).
Statistical analysis
Data in the text and tables are presented as the mean ± SD
or median with the interquartile range in parentheses, as
appropriate. Dichotomous variables were expressed as
frequencies and percentages. Variables were assessed using
the Kolmogorov–Smirnov test to examine the distribution
type. If the data did not exhibit a normal distribution, they
were logarithmically transformed prior to analysis. Stu-
dent’s t test was used to assess the differences between the
two groups, and one-factor ANOVA was used for multiple
comparisons. The Pearson correlation was calculated to
determine the correlation between the HOMA-IR and BMI.
Significance was assumed for levels \0.05 (two-tailed).
All analyses were performed using the statistical package
SPSS version 12.0. The sample size required to study the
gene expression of the transcription factors and proteins in
adipocytes and AT was calculated for a 30 % change in the
global gene expression between patients with and without
IR (Tinahones et al. 2010), 80 % power and an alpha error
of 0.05; a sample size of 23 patients per group was needed
to meet these requirements.
Results
Demographic, anthropometric, and biochemical
characteristics
One hundred and fifteen subjects underwent a Roux-en-Y
gastric bypass for morbid obesity (51 %), Nissen fundo-
plication (27 %), Heller cardiomyotomy type (6 %), elec-
tive cholecystectomy (9 %), and other (7 %). Subjects had
a mean age of 40 ± 10 years, and included 68 women
(59 %) and 47 men (41 %). Patients were classified
according to the World Health Organization BMI catego-
ries. Thus, 22 subjects had normal weight (19 %), 27
(24 %) were overweight, 8 (7 %) were class I obese, 4
(3 %) were class II obese, and 54 (47 %) were class III
obese. The results of the present study were evaluated
based on the presence of (1) IR, (2) MetS, (3) variants in
genes related to BCAA metabolism or (4) other genetic
variants.
Insulin resistance
Of 115 participants, 49 subjects were considered non-IR
(42 %), and 66 subjects were classified as IR (58 %). The
demographic, anthropometric, and clinical data from both
non-IR and IR subjects are provided in Table 1. Patients
with IR had a higher BMI, body fat mass percentage,
adipocyte area, and higher levels of HOMA-IR, serum
glucose, insulin, leptin, and CRP (p \ 0.005).
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Interestingly, the median adipocyte area in non-IR subjects
was significantly lower than that in subjects with IR
(p \ 0.005), as shown in Table 1. The Gaussian distribu-
tion curve showed that the percentage of small adipocytes
was higher in non-IR subjects than in subjects with IR;
conversely, subjects with IR had larger adipocytes than
those of non-IR subjects, as shown in Fig. 1.
Gene expression of C/EBPa, PPARc2, SREBP-1, PPARa,
UCP1, leptin receptor, leptin, adiponectin, and TNFa in
omental AT and adipocytes The gene expression in adi-
pocytes and AT was evaluated in a subgroup of 51 subjects.
The demographic, biochemical, and anthropometric
parameters are shown in Table 2.
Figure 2 shows the mRNA levels of the different genes
that were investigated in the present study. There was a
large variation in the expression levels of the different
target genes, and there was no difference between the
different genes according to the BMI (data no shown). The
expression of adipogenic and lipogenic genes was assessed
in AT and adipocytes (Fig. 2a, b). No significant change
was observed for C/EBPa and PPARc2 between IR and
non-IR subjects, suggesting a low level of adipogenesis in
both groups. However, the expression of the SREBP-1 gene
in IR subjects was significantly increased in the adipocytes
(Fig. 2b), indicating that increased insulin levels also
increased the expression of this lipogenic transcription
factor in the adipocytes. These data are consistent with the
Table 1 Demographic, anthropometric, and serum biochemical






Gender (F/M) 27/22 41/25 NS
Age (years) 41 ± 10 39 ± 11 NS
BMI (kg/m2) 29.8 ± 10.9 44.2 ± 11.8 \0.001








4.9 ± 0.6 5.8 ± 0.9 \0.001
Insulin (pmol/l) 48.8 (34.4–64.6) 166.5 (109–202) \0.001
HOMA-IR 1.6 ± 0.6 5.4 ± 3.2 \0.001
Triglycerides
(mmol/l)
2.0 (1.2–2.5) 1.9 (1.4–2.4) NS
Cholesterol
(mmol/l)
4.9 ± 1.0 4.6 ± 0.8 NS
HDL (mmol/l) 1.1 ± 0.4 1.0 ± 0.3 NS
LDL (mmol/l) 2.8 ± 0.8 2.6 ± 0.6 NS
Apo A
(mmol/l)
3.5 ± 0.9 3.4 ± 0.7 NS
Apo B
(mmol/l)
2.6 ± 0.7 2.5 ± 0.6 NS
Adiponectin
(mg/l)
9.6 ± 5.0 8.0 ± 2.3 NS
Leptin (mg/l) 21.1 (7.1–22.5) 69.4 (26.6–102.6) \0.001





























Fig. 1 Adipocyte area from the visceral adipose tissue of insulin (IR)
and non-insulin resistance (non-IR) subjects. The white bars represent
the adipocyte area from the subjects with IR, and the black bars
represent those with non-IR. a Representative photographs of the
adipocyte area from lean subjects, b subjects with both class III
obesity (BMI 40 kg/m2) and IR, and c subjects with both class III
obesity (BMI 62 kg/m2) and IR; the photographs show increased
macrophage infiltration and crown-like structures
Table 2 Demographic, anthropometrical, and serum biochemical






Gender (F/M) 13/13 14/11 NS
Age (years) 43 (38–50) 40 (32–46) NS
BMI (kg/m2) 27.2 (23.9–28.8) 39.6 (30.7–53.3) \0.001








4.8 (4.6–5.1) 5.6 (4.8–6.3) \0.005
Insulin
(pmol/l)
50.9 (36.6–66.7) 119 (108–156) \0.001
HOMA-IR 1.7 (1.2–2.0) 4.5 (3.8–5.5) \0.001
HDL (mmol/l) 0.90 (0.72–1.20) 0.85 (0.75–1.02) NS
Adiponectin
(mg/l)
7.3 (5.9–9.0) 5.5 (5.2–8.2) NS
Leptin (mg/l) 16 (6.8–82.4) 75.2 (42.6–93.7) NS
CRP (mg/l) 26 (4–56) 83 (27–100) \0.05
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important role of SREBP-1 in the expression of genes
involved in fatty acid synthesis and is also consistent with
the significant increase in the adipocyte area (4,680 lm2)
compared with that in patients without IR (2,869 lm2).
For the genes related to fatty acid oxidation, such as
PPARa and UCP1, there were no differences due to the
dispersion of the values (data no shown). We compared the
expression of genes involved in endocrine function and
inflammation in AT and adipocytes (Fig. 2c, d). For the
inflammatory and anti-inflammatory genes, there was a
significantly higher expression of TNFa in both adipocytes
and AT, lower adiponectin gene expression in adipocytes,
and higher leptin gene expression in the AT of subjects
with IR.
Serum BCAA levels and omental adipose tissue BCAT2 and
BCKDH 1Ea gene expression As expected, we observed
a significant positive correlation between BMI and HOMA-
IR (r = 0.64; p \ 0.001), as shown in Fig. 3a. In addition,
we found a significant positive correlation between R
BCAA and HOMA-IR (r = 0.45; p \ 0.001) as shown in
Fig. 3b. Interestingly, our data clearly showed that the
expression of the BCAT2 and BCKDH 1Ea genes in AT
was significantly reduced in subjects with IR, as shown in
Fig. 3c.
Metabolic syndrome
Subjects were also classified according to the diagnosis of
MetS. Approximately 50 % of the 115 subjects had MetS,
and the most common factor in these subjects was low
HDL concentration, followed by obesity, hypertriglyceri-
demia, hyperglycemia, and hypertension, as shown in
Table 3. Interestingly, subjects with only 2 MetS factors
showed IR, and those with 5 MetS risk factors had the
highest HOMA-IR (9.5), Fig. 4a.
Serum branched-chain amino acid levels and MetS We
investigated whether subjects with MetS showed changes
in the serum concentration of BCAAs. Interestingly, as
shown in Fig. 4c, there was a significant increase in the
serum BCAA concentration in subjects with MetS
(636 ± 271 lmol/l) relative to that in the subjects without
MetS (475 ± 162 lmol/l) (p \ 0.05). This result implied
that subjects with MetS had a serum BCAA concentration
approximately 34 % higher than that in subjects without
MetS, and as expected, subjects with MetS had signifi-
cantly higher HOMA-IR, Fig. 4b.
BCAA metabolism gene variants
To understand why obese subjects with MetS who develop
IR had lower AT expression of the enzymes involved in
BCAA metabolism, we explored whether this finding could
be partly associated with the presence of a polymorphism
in BCAT2 or BCKDH. We studied two SNPs of BCAT2 and
one SNP of BCKDH; these SNPs have a frequency higher
of 10 % in HapMap (EMBL-EBI 2013). Although one
BCAT2 (rs73587806) gene variant did not show any asso-
ciation with the serum BCAA concentration, the subjects
Fig. 2 Visceral adipose tissue
and adipocyte mRNA gene
expression of C/EBPa, PPARc2,
SREBP-1, leptin receptor (LR),
leptin, adiponectin (AD), and
TNFa. Black bars, subjects
without insulin resistance (non-
IR); white bars, subjects with
insulin resistance (IR)
*p \ 0.05, **p \ 0.01
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with the BCAT2 (rs11548193) or BCKDH (rs45500792)
gene variants had a significantly lower serum BCAA
concentration than that of the wild-type subjects. In fact,
the subjects with the BCAT2 or the BCKDH gene variants
showed approximately 29 or 17 %, respectively, lower
serum BCAA levels compared with wild-type subjects,
Fig. 5a. Interestingly, although there were no significant
differences in HOMA between subjects with the gene
variants for BCAT2 or BCKDH compared to wild-type
subjects, those with the BCAT2 variant tended to have a
lower HOMA-IR (3.08 ± 2.8) than wild-type subjects
(4.35 ± 3.2).
Association of ABCA1, FTO, GFOD2, PPARc,
and TCF7L2 gene variants with serum insulin
and HOMA-IR
To further assess whether the presence of specific SNPs
with a high frequency in the Mexican population that have
been associated with obesity and IR could explain the
metabolic phenotype, particularly the serum insulin levels
and HOMA-IR, we analyzed the SNPs for ABCA1, FTO,
GFOD2, PPARc, and TCF7L2 in subjects with IR or MetS.
The subjects with the presence of the ABCA1 polymor-
phism and the FTO risk allele showed significantly higher
insulin concentration and HOMA-IR compared with sub-
jects without the variant, as shown in Fig. 5b. Interestingly,
37 % of subjects with the FTO risk allele were IR
(p \ 0.05), and 10 % of the subjects with the ABCA1
polymorphism had MetS. There was no significant asso-
ciation between the GFOD2, PPARc, TCF7L2 polymor-
phisms, and IR or MetS. None of these SNPs were
associated with the serum BCAA concentration. Nonethe-
less, only subjects with the ABCA1 polymorphism tended
to have higher serum BCAA concentration (842 ± 210)
than wild-type subjects (518 ± 220).
Discussion
Obesity is a multifactorial disorder influenced by a mixture
of genetic, behavioral, life-style, over nutrition, and envi-
ronmental factors. These factors and their interactions
Fig. 3 Associations between body mass index, HOMA-IR, BCCAs,
omental adipose tissue BCAT, and BCKDH gene expression.
a Bivariate correlation between HOMA-IR and BMI, r = 0.64
(Pearson test), p \ 0.001. b Bivariate correlation between R BCAAs
and HOMA-IR, r = 0.45 (Pearson test), p \ 0.001. c Relationship
between visceral adipose tissue gene expression of the BCKDH and
BCAT2 in subjects with insulin resistance (IR) and non-insulin
resistance (non-IR) *p \ 0.05 (c)









Men \ 1 mmol/l 35 (74 %) 47 (69 %) 82 (74 %)
Women \ 1.25 mmol/l
Waist circumference
Men [ 90 cm 30 (64 %) 50 (74 %) 80 (70 %)
Women [ 80 cm
Serum triglycerides
C1.65 mmol/l 33 (70 %) 23 (34 %) 56 (50 %)
Serum glucose
C5.5 mmol/l 16 (34 %) 25 (37 %) 41 (35 %)
Blood pressure
[130/85 mmHg 14 (30 %) 20 (29 %) 34 (30 %)
Diagnosis of MetS 27 (57 %) 30 (44 %) 57 (50 %)
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cause expansion in fat mass. Our results revealed some of
the factors involved in the development of the AT dys-
function associated with obesity. The overnutrition that is
reflected by an increase in plasma amino acid concentra-
tions (Tovar et al. 1996) produces an excess of amino acids
that must be rapidly oxidized in the liver by the amino
acid-catabolizing enzymes. However, BCAAs undergo a
different metabolic fate due to the absence of BCAT2 in the
liver. BCAAs bypass the liver and are selectively metab-
olized in extra hepatic tissues, mainly skeletal muscle, AT
and the brain (Brosnan and Brosnan 2006). Our findings
and previous work (Lackey et al. 2013) indicate that
omental white adipose tissue plays an important role in
BCAA homeostasis because this organ has a large capacity
to catabolize BCAAs, and the presence of insulin resistance
or metabolic syndrome downregulates AT BCAA pathway
enzyme expression. Interestingly, we observed that the
higher the BMI and IR the higher the serum BCAA con-
centrations possibly due to a decrease in the expression of
the two key BCAA enzymes, BCAT2 and BCKDH E1a in
AT. The results support the concept that the BCAA cata-
bolic pathway in adipose tissue is sensitive to changes in
insulin action and that insulin resistance impairs efficient
BCAA catabolism in AT (Lackey et al. 2013). These
results suggest that hypertrophic adipocytes develop met-
abolic inflexibility, which may prevent the utilization of
BCAA. It has been proposed that high tissue and blood
concentrations of BCAAs in human obesity cause or
exacerbate IR through mechanisms involving leucine; this
amino acid promotes the activation of the mechanistic
target of rapamycin (mTOR) in muscle (Tremblay et al.
2005) and the phosphatidylinositol 3-kinase signaling
pathways (Nellis et al. 2002). High serum BCAA (espe-
cially leucine) concentrations were associated with obesity
and hyperinsulinemia, a finding that is consistent with
earlier studies suggesting that BCAAs may augment the
pancreatic secretion of insulin in the IR state (Pietilainen
et al. 2008).
Fig. 4 Association between HOMA-IR, metabolic syndrome and
BCAA. Relationship between HOMA-IR and metabolic syndrome
(MetS) risk factors (a). Relationship between HOMA-IR and MetS
(b); Relationship between the R BCAAs and MetS (c). The white bars
represent subjects with MetS, and the black bars represent those
without MetS
Fig. 5 Relationship between R BCAAs and the presence of the
genetic variants of BCKDH and BCAT2 *p \ 0.05 (a). Relationship
between insulin and HOMA-IR and the presence of the genetic
variants of ABCA1 and FTO (b) *p \ 0.05
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Because obesity is often accompanied by adipocyte
metabolic dysfunction we explored other factors involved
in AT dysfunction such as specific variants in the genes of
the BCAT and BCKDH enzymes that could be involved in
the regulation of BCAA. Little is known regarding whether
the presence of gene variants of the key enzymes in BCAA
catabolism is associated with serum BCAA concentration.
Interestingly, our data showed that subjects with the gene
variants for BCAT2 or BCKDH have significantly lower
serum concentrations of BCAAs. The BCAT2 gene variant
generates a BCAT2 protein containing a threonine instead
of an arginine; this change can affect the substrate- or
cofactor-binding sites, altering BCAT2 activity. In con-
trast, the change in the BCKDH gene variant is located in
the 50 UTR that can modify a potential response element,
subsequently modifying the BCKDH expression. These
data suggest that subjects with these gene variants may
have higher enzyme activity compared with wild-type
subjects; however, detailed studies are needed to under-
stand these changes. Interestingly, we also examined sev-
eral polymorphisms that included ABCA1, FTO, PPARc,
and TCFL2, but none of them were associated with serum
BCAA concentration. Our results can partially explain the
increase in the serum BCAA concentration of obese sub-
jects through (1) decreased expression of the BCAA
catabolism enzymes, particularly BCAT2 and BCKDH, (2)
the presence of specific gene variants of BCAT2 and
BCKDH, and (3) the amount of fat accumulation in adi-
pocytes that affects AT functionality.
Besides that, other specific variants can contribute to the
insulin resistance. In the present study, subjects with the
ABCA1 gene variant exclusive to Native American indi-
viduals (Villarreal-Molina et al. 2007), and with the FTO
variant showed higher values for the serum insulin con-
centration and HOMA-IR compared without the polymor-
phism. In addition, subjects with only two MetS risk
factors showed IR suggesting the high susceptibility of the
population studied to develop IR.
In the present study, we also observed a significant
increase in the inflammatory adipokine TNFa and a
decrease in the gene expression of adiponectin, which is an
anti-inflammatory cytokine. IR has been associated with
Fig. 6 Summary of the factors (e.g., genetic factors, biochemical
factors, endocrine factors, and inflammatory markers) and physio-
logical differences, gene expression, and environmental interactions
cause AT dysfunction by initiating a sequence leading to adipocyte
hypertrophy and inflammatory processes
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increased macrophage infiltration in AT and adipocyte size.
However, the pathogenic link between increased AT mass
and a higher risk for obesity-related disorders did not
directly involve the expression of the genes associated with
adipocyte differentiation, fatty acid oxidation, or thermo-
genesis due to individual variability. Variations in the
expression of obesity-related genes in fat are influenced by
the complex interactions between genes and the environ-
ment, the contributions of which are difficult to
disentangle.
Enlarged adipocyte size is associated with IR and
increased adipokine production and secretion. In our study,
IR was associated with increased adipocyte area and
increased AT mass; these changes occurred due to inade-
quate vascularization and thus might lead to hypoxia,
macrophage infiltration, and inflammation. The adipokines,
secreted by hypertrophied adipocytes, attract macrophages
that are dispersed throughout the tissue or clustered around
adipocytes in ‘‘crown like structures’’; these macrophages
secrete cytokines that contribute to the low-grade inflam-
mation seen in obesity. Chronic inflammation is another
hallmark of unhealthy adipocytes and is most likely a
major mechanism responsible for lowering HDL during
obesity (McGillicuddy et al. 2011).
AT dysfunction is a primary defect in human obesity,
which involves complex pathophysiological mechanisms
that evolve over time and are largely beyond individual
control, and may link obesity to several health problems,
including increased risk for type 2 diabetes, fatty liver, and
cardiovascular disease. Here, we propose a process for how
different factors (e.g., genetic factors, BCAA metabolism,
endocrine factors, and inflammatory markers) and physio-
logical differences, gene expression, and environmental
interactions cause AT dysfunction by initiating a sequence
leading to adipocyte hypertrophy and inflammatory pro-
cesses, Fig. 6. As a consequence, impaired AT function
contributes to a proinflammatory, atherogenic, and diabe-
togenic state and may be mechanistically linked to the
development of obesity-associated disorders. The com-
plexity of obesity, along with the potential for disease
progression and the heterogeneity of individuals with
obesity, must be considered when designing treatment
strategies.
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